Brought to you by 
Baxter buys Oncaspar portfolio from Sigma-Tau for $900mm
30 Jan 2023
Executive Summary
Baxter International Inc. paid $900mm cash to buy the Oncaspar (pegaspargase) portfolio from Sigma-Tau Finanziaria SPA. Baxter’s Baxter BioScience division (soon to become the independent publicly traded Baxalta Inc.) will hold rights to the products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter buys Oncaspar portfolio from Sigma-Tau for $900mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice